Krista Hollis
Nurse Practitioner · Forest City, PANPI 1992138135
Payments from drug & device makers
Across 275 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$948
- AstraZeneca$531
- Lilly USA, LLC$484
- GSK$413
- Otsuka America Pharmaceutical, Inc.$299
- Boehringer Ingelheim$281
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $948 |
| AstraZeneca | 31 | $531 |
| Lilly USA, LLC | 39 | $484 |
| GSK | 26 | $413 |
| Otsuka America Pharmaceutical, Inc. | 13 | $299 |
| Boehringer Ingelheim | 16 | $281 |
| AbbVie | 10 | $170 |
| Abbott | 9 | $148 |
| Lundbeck LLC | 7 | $145 |
| Bayer | 8 | $137 |
| Amgen | 7 | $117 |
| Daiichi Sankyo Inc. | 5 | $110 |
| E.r. Squibb & Sons, L.L.C. | 7 | $98 |
| Amarin Pharma, Inc. | 6 | $97 |
| SK Life Science, Inc. | 4 | $69 |
| Astellas Pharma US Inc | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Pfizer | 4 | $57 |
| Exact Sciences | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Radius Health, Inc. | 3 | $39 |
| Merck | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Johnson & Johnson | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Eisai Inc. | 1 | $12 |
How this compares
$4,540 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $127,079 |
| OzempicSemaglutide | 81 | $74,286 |
| JardianceEmpagliflozin | 79 | $72,594 |
| RybelsusSemaglutide | 26 | $38,486 |
| FarxigaDapagliflozin Propanediol | 25 | $24,651 |
| MyrbetriqMirabegron | 18 | $17,560 |
| TrulicityDulaglutide | 18 | $16,811 |
| XareltoRivaroxaban | 16 | $16,682 |
| WegovySemaglutide | 12 | $15,864 |
| TradjentaLinagliptin | 12 | $14,732 |
| JanuviaSitagliptin Phosphate | 16 | $12,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $9,964 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,811 |
| Rosuvastatin Calcium | 347 | $7,674 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $948 | $128,636119 claims |
| PfizerEliquis | $57 | $127,079130 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $281 | $93,970105 claims |
| AstraZenecaFarxiga | $531 | $24,65125 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $413 | $24,18347 claims |
| MerckJanuvia, Janumet | $36 | $19,44928 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $17,56018 claims |
| Lilly USA, LLCTrulicity | $484 | $16,81118 claims |
| Johnson & JohnsonXarelto | $22 | $16,68216 claims |
| AbbVieSynthroid | $170 | $2,12126 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $1,16711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Forest City
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.